GLP 1 Receptor Agonism Counteracts Body Wide Aging

NotebookLM: "...various therapeutic interventions and pharmacological agents with potential applications in treating age-related diseases and extending longevity [are discussed]. ... the effects of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs), such as semaglutide and exenatide, exploring their impact on cognitive function [the hypothalamus], cardiovascular outcomes, and systemic anti-aging mechanisms across multiple tissues. Other documents detail research into Hyperbaric Oxygen Therapy (HBOT), assessing its influence on aging hallmarks like telomere length, cognitive enhancement, and cellular mechanisms related to oxidative stress. Additionally, two other interventions are covered: metformin's association with exceptional longevity in women with type 2 diabetes, and the potential of mTOR inhibitors (like rapamycin), including analysis of their efficacy as an anti-aging strategy and their associated renal toxicity risks. Finally, one source briefly mentions Therapeutic Plasma Exchange and its connection to aging biomarkers."